Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Rogerson

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
MMWR. Morbidity and Mortality Weekly Report|May 25, 2023
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023Ruth Link-Gelles, Zachary A Weber, Sarah E Reese, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
Lancet Regional Health. Americas|October 3, 2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysisAmanda B Payne, Steph Battan-Wraith, Elizabeth A K Rowley, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
Vaccine|July 15, 2025
Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive ageEmily L Reeves, Kristin Dascomb, Stephanie A Irving, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2024
Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United StatesMark W Tenforde, Emily L Reeves, Zachary A Weber, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults - United States, 2024-25 seasonJennifer DeCuir, Emily L Reeves, Zachary A Weber, et al.
MMWR. Morbidity and Mortality Weekly Report|February 27, 2025
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025Ruth Link-Gelles, Sean Chickery, Alexander Webber, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
MMWR. Morbidity and Mortality Weekly Report|May 25, 2023
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023Ruth Link-Gelles, Zachary A Weber, Sarah E Reese, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
Lancet Regional Health. Americas|October 3, 2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysisAmanda B Payne, Steph Battan-Wraith, Elizabeth A K Rowley, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
Vaccine|July 15, 2025
Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive ageEmily L Reeves, Kristin Dascomb, Stephanie A Irving, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2024
Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United StatesMark W Tenforde, Emily L Reeves, Zachary A Weber, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults - United States, 2024-25 seasonJennifer DeCuir, Emily L Reeves, Zachary A Weber, et al.
MMWR. Morbidity and Mortality Weekly Report|February 27, 2025
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025Ruth Link-Gelles, Sean Chickery, Alexander Webber, et al.
Pageof 4